Time filter

Source Type

Djermoune S.O.,University of Monastir | Oukkal M.,Clinique doncologie medicale Amine Zirout | Bouzid K.,Service doncologie medicale CPMC | Denine R.,University dAlger | Bonnabry P.,University of Geneva
Pharmacien Hospitalier et Clinicien | Year: 2015

Introduction: The Concord study published in the journal. The lancet oncology in July 2008 on the future of oncological diseases which covered 1.9 million people from 31 countries led us to analyze the vulnerability of anticancer drug therapy in Algeria countries reported to have the lowest survival rates at 5 years of the study. The aim of our study was to contribute to improve the anticancer drug management in hospitals, by a prospective risk analysis. Materials and methods: We analyzed the existing process at the Amine Zirout clinic, part of the University Hospital Beni Messous, Algiers, Algeria by the Failure Modes and Criticality Effect Analysis (FMECA) method. Results/discussion: The process has been described, the risks have been identified, the criticality indexes (CI) calculated, the causes of identified deficiencies and the impact of improvement measures estimated by an interdisciplinary group of experts (physicians, pharmacists and nurses). The sum of the CI of 30 identified failure modes was estimated to be 6511 in a decentralized system. The main causes identified were related to an insufficient regulatory basis to secure the clinical cancer chemotherapy process in Algeria. The estimation of the impact ("FMECA after") of an organization in a centralized system gave a sum of CI. = 4648 and computerization of various stages gave a sum of CI. = 3154 suggesting a potential 50% security gain of the criticality of the process. Conclusion: Our study was the starting point of an active and dynamic continuous analysis and risk reduction approach at the Amine Zirout clinic (Algiers, Algeria). On the other hand, it will allow recommendations to secure by regulation the cancer chemotherapy process and the adequate training of those responsible for the anticancer drug process and re-engineering in a centralized and computerized system, which means economic efficiency and safety improvement for the institution. © 2015 Elsevier Masson SAS.


Djermoune S.O.,University of Monastir | Oukkal M.,Clinique dOncologie Medicale Amine Zirout | Bouzid K.,Service dOncologie Medicale CPMC | Denine R.,University dAlger | And 2 more authors.
Pharmacien Hospitalier et Clinicien | Year: 2016

Introduction. The Concord study published in the journal The lancet oncology in July 2008 on the future of oncological diseases which covered 1.9 million people from 31 countries led us to analyze the vulnerability of anticancer drug therapy in Algeria countries reported to have the lowest survival rates at 5 years of the study. The aim of our study was to contribute to improve the anticancer drug management in hospitals, by a prospective risk analysis. Materials and methods. We analyzed the existing process at the Amine Zirout clinic, part of the University Hospital Beni Messous, Algiers, Algeria by the Failure Modes and Criticality Effect Analysis (FMECA) method. Results/discussion. The process has been described, the risks have been identified, the criticality indexes (CI) calculated, the causes of identified deficiencies and the impact of improvement measures estimated by an interdisciplinary group of experts (physicians, pharmacists and nurses). The sum of the CI of 30 identified failure modes was estimated to be 6511 in a decentralized system. The main causes identified were related to an insufficient regulatory basis to secure the clinical cancer chemotherapy process in Algeria. The estimation of the impact ("FMECA after") of an organization in a centralized system gave a sum of CI = 4648 and computerization of various stages gave a sum of CI = 3154 suggesting a potential 50% security gain of the criticality of the process. Conclusion. Our study was the starting point of an active and dynamic continuous analysis and risk reduction approach at the Amine Zirout clinic (Algiers, Algeria). On the other hand, it will allow recommendations to secure by regulation the cancer chemotherapy process and the adequate training of those responsible for the anticancer drug process and re-engineering in a centralized and computerized system, which means economic efficiency and safety improvement for the institution. © 2015 Elsevier Masson SAS.

Loading Service doncologie medicale CPMC collaborators
Loading Service doncologie medicale CPMC collaborators